{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:25:43Z","timestamp":1789475143423,"version":"build-2803163510"},"reference-count":17,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cephalalgia"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the achievement of the International Headache Society (IHS) higher standards for migraine prevention in patients treated with calcitonin gene-related peptide monoclonal antibodies (CGRP mAbs) in real-world practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 307 migraine patients treated with CGRP mAbs at a single center. Monthly migraine days (MMDs) were assessed at baseline and during follow-up (1\u201324 months). According to IHS recommendations, migraine control was categorized as optimal (&lt;4 migraine days\/month), modest (4\u20136 days\/month), or insufficient (&gt;6 days\/month). Patients were further classified by the timing of achieving optimal control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The percentage of patients achieving a\u2009\u2265\u200950% reduction in MMDs increased from 36.2% at month 1 to 71.0% at month 24; optimal control increased from 15.0% to 38.8%. Among patients with a\u2009\u2265\u200950% response, 38.7\u201355.7% achieved optimal control during follow-up. Migraine freedom remained relatively uncommon (1.6\u201310.1%). Patients who achieved optimal control early (\u22643 months) had a lower baseline migraine burden, whereas nonachievers had a higher baseline disease burden and more prior preventive treatment failures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CGRP mAbs were associated with substantial reductions in migraine frequency; however, achieving optimal control and migraine freedom remains challenging in real-world practice, particularly in patients with a higher baseline burden.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03331024261453284","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:07:08Z","timestamp":1780304828000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world achievement of higher standards for migraine prevention with CGRP monoclonal antibodies"],"prefix":"10.1177","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0320-8993","authenticated-orcid":false,"given":"Keisuke","family":"Suzuki","sequence":"first","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7430-2078","authenticated-orcid":false,"given":"Shiho","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saro","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mukuto","family":"Shioda","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Fujita","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Haruyama","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Hida","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-4734","authenticated-orcid":false,"given":"Koichi","family":"Hirata","sequence":"additional","affiliation":[{"name":"Dokkyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251320608"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14692"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70562"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12287-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251414659"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241269735"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32504-8"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2006.00602.x"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32162-0"},{"key":"e_1_3_3_11_2","first-page":"927","article-title":"Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world","volume":"95","author":"Caronna E","year":"2024","unstructured":"Caronna E, Gallardo VJ, Egeo G, et al. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world. J Neurol Neurosurg Psychiatry 2024; 95: 927\u2013937.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01552-x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-025-02011-5"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14090948"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-023-00525-x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14629"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.0368"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-023-01682-2"}],"container-title":["Cephalalgia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261453284","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03331024261453284","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03331024261453284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:16:44Z","timestamp":1780553804000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03331024261453284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1177\/03331024261453284"],"URL":"https:\/\/doi.org\/10.1177\/03331024261453284","relation":{},"ISSN":["0333-1024","1468-2982"],"issn-type":[{"value":"0333-1024","type":"print"},{"value":"1468-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"03331024261453284"}}